The Relation Between Vitamin D and Gestational Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-05

Study Completion Date

2013-08-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with the onset or first recognition during pregnancy. The prevalence of GDM varies from 1-14% due to its variability worldwide, depending on the ethnicity, race, and the diagnostic criteria being applied by each country. In addition to this, approximately 7% of all pregnancies are affected by GDM, ending up more than 200,000 women with GDM per year. A recent study of literature research indicated that Middle East and North Africa had the highest prevalence (median, 12.9%) while Europe had the lowest prevalence (median, 5.8%) in the world. In Turkey the prevalence of GDM ranges between 4-10%, based on the reports in different studies.

As a growing health concern, GDM has been associated with short and long-term detrimental health outcomes for women and their offspring. Maternal adverse effects of GDM are preeclampsia, elevated risk of development of hypertension, type 2 diabetes mellitus (T2DM), urinary tract infection and comorbidities following delivery. Macrosomia, neonatal jaundice, birth trauma, respiratory distress syndrome, hypoglycemia are included in short term consequence for the neonates whereas risk for development of impaired glucose tolerance, T2DM, obesity, vascular disorders are long term adverse effects on infant's health.

The known risk factors for GDM include family history of T2DM, maternal overweight and obesity, advanced maternal age, history of GDM, having macrosomic infant previously, prior fetal death, and race/ethnicity. In addition to these risk factors, recent studies have been suggested that maternal vitamin D deficiency may be associated with a higher risk of GDM.

Vitamin D deficiency during the pregnancy has been associated with adverse outcomes for the pregnant women, such as gestational diabetes mellitus, urinary tract infection, preeclampsia, caesarean section during labour \[25\]. Furthermore, infants born to mothers with lower vitamin D levels have been found to be associated with elevated risk of small for gestational age, low birth weight in the neonatal period, increased risk for cardiovascular disease, respiratory illnesses, type 2 diabetes mellitus in childhood and adulthood.

The aim of this study was to compare the serum 25(OH)D levels of women with and without gestational diabetes mellitus (GDM) and identify the serum 25(OH)D level associated with GDM during pregnancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D in Ectopic Pregnancies

NCT03894735

Ectopic Pregnancy Vitamin D Deficiency

COMPLETED

Correlation of Vitamin D Levels in Early Pregnancy With Gestational Diabetes and Pregnancy Outcomes

NCT05212519

GDM

UNKNOWN

Effects of Vitamin D Supplementation on Glucose Metabolism in Women With Former Gestational Diabetes Mellitus

NCT01992133

Gestational Diabetes Mellitus in Pregnancy Vitamin D Deficiency

COMPLETED NA

Effect of Vitamin D Intake in Pregnancy to Prevent Recurrence of Gestational Diabetes

NCT03701087

Vitamin D Intake in First Trimester and Incidence of Gestational Diabetes Recurrence

UNKNOWN EARLY_PHASE1

The Impact of Vitamin D Supplementation on Glucose Metabolism in Chinese Women With Former Gestational Diabetes Mellitus

NCT03138616

Gestational Diabetes Mellitus

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this observational cross-sectional study, 40 women with GDM and 40 healthy pregnant between 20-40 years in age, in their 24-28th gestational week applied to Gulhane Education and Research Hospital (Ankara, Turkey) were recruited between January 2014 to March 2014. Inclusion criteria were singleton pregnancy, aged 20-40 years, gestational age 24-28 weeks, non-history of acute or chronic diseases. The exclusion criteria included alcohol using, smoking, history of GDM, diagnosed with type 1 and 2 diabetes mellitus, preeclampsia, polycystic ovary syndrome, thyroid and parathyroid disease, metabolic bone disease, kidney disease, abnormal liver function, multiple pregnancy, or women receiving drugs related to calcium and vitamin D metabolism (with the exception of routine vitamin supplements prescribed during pregnancy). We randomly selected the 40 pregnant women diagnosed GDM by two-step procedure based on Carpenter-Coustan criteria. Women with GDM did not receive any type of the medications such as insulin or medical nutrition therapy. We also randomly selected 40 healthy pregnant women with normal serum glucose levels in the same period. This study must recruit 40 women for each group to have 80% study power with 5% type I error level to detect a clinically significant difference.

The study was approved by the ethic committee of Gulhane Education and Research Hospital, Ankara, Turkey with the number 50687469-1491-2721-13/1648.4-2882. Before commencing the research, not only women got clued in information about the study procedure and objective but also a written informed consent was obtained from all participants.

GDM screening at this hospital involves a two-step procedure. At the outset, 50 g 1 hour glucose challenge test (GCT) was used to screen for GDM at 24th and 28th weeks of gestation. Women with abnormal glucose levels ≥130 mg/dL (7.2 mmol/L) after 1 hour GCT underwent a standard 100 g 3 hour oral glucose tolerance test (OGTT) performed in the morning after eight hours overnight fasting. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL (10.0 mmol/L), 2 hours ≥ 155 mg/dL (8.6 mmol/L), and 3 hours ≥ 140 mg/dL (7.8 mmol/L).

Demographic and individual information such as maternal age, gestational week, parity were recorded. Weight and height of women with light clothes and without shoes were measured via a digital Seca Scale. BMI (Body Mass Index) was calculated by using the following formula: BMI=Weight (kg)/\[Height (m) × Height (m)\] and evaluated based on classification of (World Health Organisation) WHO as follows: \>18.5 kg/m2 defined as underweight, 18.5-24.9 kg/m2 defined as normal weight range, 25.0-29.9 kg/m2 defined as overweight and ≥30.0 kg/m2 defined as obese. Investigators collected blood samples from each women between 24th and 28th weeks of pregnancy during their scheduled antenatal visit to determine the serum 25-hydroxyvitamin D \[(25OHD)\] concentration.

Levels of 25(OH)D on serum was measured by high performance liquid chromatography (HPLC) in biochemistry laboratory at Gulhane Education and Research Hospital. Investigators used clinical cutoffs based Institute of Medicine (IOM) criteria to categorize 25(OH)D levels: severe deficiency (\<10 ng/mL), deficiency (10-20 ng/mL) and insufficiency (20-30 ng/mL).

Firstly, the variables were tested using Kolmogorov-Smirnov test to determine whether they are normally distributed. Descriptive analyses were presented as mean±standard deviation (SD) for normally distributed variables. Since the maternal age, serum 25(OH)D, log-transformed 50 g 1 hour GCT and log-transformed fasting blood glucose values were normally distributed; the Student's t-test was used to compare these parameters between women with and without GDM. Descriptive analyses were presented as median(min-max) for the non-normally distributed. Since the gestational age, gravity, and parity were not normally distributed; Mann-Whitney U test was used to compare these parameters between groups. Chi square test was used for categorical variable to compare the proportions in different groups. As both parameters were normally distributed, the correlation coefficients and their significance were calculated using the Pearson test. For the multivariate analysis, the possible factors identified with univariate analyses were further entered into the logistic regression analysis to determine independent predictors of women outcome. Hosmer-Lemeshow goodness of fit statistics were used to assess model fit. A 5% type-I error level was used to infer statistical significance. Receiver operating characteristics (ROC) analysis was done to identify the optimal cutoff point values of maternal serum 25OHD levels. All the data collected from the participants were analyzed using Statistical Package for the Social Sciences (SPSS) version 22.0 (SPSS Inc., Chicago, Illinois, USA) and p\<0.05 was considered statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deficiency, Vitamin D Diabetes, Gestational

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women with gestational diabetes mellitus

GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).

No interventions assigned to this group

Women non gestational diabetes mellitus

Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton pregnancy,
* Aged in 20-40 years,
* Gestational age 24-28 weeks,
* Non-history of acute or chronic diseases.

Exclusion Criteria

* History of GDM,
* Type 1 and 2 diabetes mellitus,
* Preeclampsia,
* Polycystic ovary syndrome,
* Thyroid disease
* Parathyroid disease,
* Metabolic bone disease,
* Kidney disease,
* Abnormal liver function,
* Multiple pregnancy, or
* Women receiving drugs related to calcium and vitamin D metabolism (with the exception of routine vitamin supplements prescribed during pregnancy)

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes